NNVC - NanoViricides, Inc.
| Previous Close | 0.3000 |
| Open | 0.3090 |
| Bid | 0.3277 x 2200 |
| Ask | 0.3390 x 800 |
| Day's Range | 0.3010 - 0.3456 |
| 52 Week Range | 0.2500 - 1.2300 |
| Volume | 203,938 |
| Avg. Volume | 139,396 |
| Market Cap | 22.737M |
| Beta (3Y Monthly) | -0.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1320 |
| Earnings Date | Nov 19, 2018 - Nov 23, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.30 |
- PR Newswire•yesterday
NanoViricides CEO Dr. Irach Taraporewala Presents a Letter to Shareholders
SHELTON, Conn., Oct. 22, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), reports that its new CEO, Dr. Irach Taraporewala, has presented a letter to the shareholders of the Company. The letter provides a Corporate Update along with his assessment of where the Company stands today. Dr. Taraporewala also explains his expertise in taking a novel drug from pre-clinical development through human clinical trials in the letter.
- PR Newswire•8 days ago
NanoViricides Has Filed its Annual Report, Company Reports Strong Progress in Advancement of HerpeCide Program
SHELTON, Conn., Oct. 15, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), reports that it has filed its annual report (Form 10-K) for the financial year ending June 30, 2018, with the Securities and Exchange Commission (SEC) on Friday, October 12, 2018. The Company reported that, as of June 30, 2018, we had cash and cash equivalent balance of approximately $7.08 Million. In comparison, as of June 30, 2017, we had cash in hand of approximately $15.10Million.
- PR Newswire•25 days ago
NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1
SHELTON, Conn., Sept. 28, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer: NNVC) (the "Company"), a global leader in developing nanomedicines to attack pathogenic viruses, announced today that it will be presenting at the MicroCap Investment Conference. Dr. Irach B. Taraporewala, Chief Executive Officer of the Company, will present a corporate overview and discuss the Company's progress in taking its first drug candidate into human clinical trials. The Company has a broad and deep pipeline of drug candidates based on its unique, post-immunotherapeutic "bind-encapsulate-destroy" "nanoviricide®" technology platform, that addresses a market space of $40 Billion to $70 Billion.
- Simply Wall St.•27 days ago
Who Are The Major Shareholders Of NanoViricides Inc (NYSEMKT:NNVC)?
A look at the shareholders of NanoViricides Inc (NYSEMKT:NNVC) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companiesRead More...
- PR Newswire•2 months ago
NanoViricides Inc. to Present at 20th Annual Rodman & Renshaw Conference in NYC on Sept 6th
SHELTON, Conn., Sept. 5, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer: NNVC) (the "Company"), a global leader in developing nanomedicines to attack viruses, announced today that it will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Dr. Anil Diwan, President and Chairman of the Board of NanoViricides, will present a corporate overview and discuss the Company's progress in taking its first drug candidate into human clinical trials. The Company has updated its corporate "fact sheet", or brochure, and it is available on the Company's website at www.nanoviricides.com.
- GlobeNewswire•2 months ago
President and Chairman of the Board of Directors, Anil R. Diwan, Ph.D., of NanoViricides, Inc., Discusses Company Updates with Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
NanoViricides, Inc. (NNVC), (the “Company”) announced President and Chairman, Dr. Anil Diwan’s interview on Uptick Newswire’s “Stock Day” Podcast. Everett Jolly invited NanoViricides, Inc.’s President and Chairman of the Board of Directors, Anil R. Diwan, Ph.D., back for the first time in over a year to the “Stock Day” podcast for an update.
- PR Newswire•3 months ago
NanoViricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study
SHELTON, Conn., Aug. 7, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer: NNVC) (the "Company") reports that its anti-Shingles drug candidates were effective in ameliorating pain sensations in an animal model of abnormal pain. A characteristic excruciating pain is a debilitating pathology of shingles presentation. Thus a direct pain-reducing effect of the Company's anti-shingles drug candidates would be very important in ameliorating the pathology of shingles, in addition to the already demonstrated significant antiviral effect. More importantly, the characteristic pins-and-needles pain in shingles can persist in some patients even after the shingles dermal presentation has resolved, for six months or longer.
- PR Newswire•3 months ago
NanoViricides, Inc. Welcomes Dr. Irach Taraporewala as the New CEO
SHELTON, Conn., July 23, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer: NNVC) (the "Company"), is pleased to announce that the Company's Board has appointed Dr. Irach Taraporewala as the new Chief Executive Officer (CEO). Dr. Irach B. Taraporewala is a seasoned pharmaceutical executive with over 25 years of experience in drug development and regulatory strategy.
- PR Newswire•3 months ago
NanoViricides Provides Update on Recent Events
SHELTON, Conn., July 12, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that it is financially sound and that its drug candidates in the HerpeCide™ program are moving towards the clinical stage at a reasonable pace. On July 10, 2018, Dr. Milton Boniuk resigned from his position as a member of the Board of Directors and from all Committees of the Board. Another Director, Dr. Mukund Kulkarni, who had previously resigned solely from the Audit Committee, has rescinded his resignation and is continuing as a member of the Audit Committee.
- PR Newswire•4 months ago
Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research
The presentation showed that nanoviricide topical treatment of the cultured human skin was highly effective. In addition, the treatment was well tolerated with no apparent adverse effects. The Company is further advancing these drug candidates towards selection of a final candidate and formal safety/toxicology studies as needed for filing a Investigational New Drug Application (IND) with the US FDA.
- ACCESSWIRE•4 months ago
Wired News – AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress
LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on AbbVie Inc. (NYSE: ABBV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ABBV as the Company’s latest news hit the wire. On June 15, 2018, the Company announced that it has presented investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase-3 MURANO trial, assessing venetoclax in combination with rituximab (VenR) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) during the 23rd European Hematology Association (EHA) Annual Congress, Stockholm, held on June 16, 2018.
- PR Newswire•5 months ago
NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates
SHELTON, Conn., May 22, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its third quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission yesterday. The Company reported that it had approximately $10.95 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of 2.29M, as of March 31, 2018, the end of the reporting period. The Company's research and development (R&D) expenditure of approximately $1.03M in the current quarter was in line with our budgeted estimates.
- Associated Press•5 months ago
NanoViricides: Fiscal 3Q Earnings Snapshot
The Shelton, Connecticut-based company said it had a loss of 3 cents per share. The company's shares closed at 53 cents. A year ago, they were trading at $1.29. _____ This story was generated by Automated ...
- PR Newswire•6 months ago
NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today
SHELTON, Conn., April 9, 2018 /PRNewswire/ -- NanoViricides, Inc. (the "Company") reports that its drug candidates in the HerpeCide™ program have been found to be safe based on multiple parameters in the recently completed initial non-GLP safety/toxicology study. No clinically observable adverse safety and toxicology effects were seen in this study of the Company's optimized topical dermal drug candidates. The drug candidates tested in this safety/toxicology study have previously shown broad-spectrum effectiveness against alphaherpesviruses, i.e.
- PR Newswire•7 months ago
NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin
SHELTON, Conn., March 19, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") has announced that it has expanded its in vivo testing agreement with the University of Wisconsin to encompass testing its topical anti-herpes agents in animal models of HSV-induced dermal, ocular and genital herpes virus infections. NanoViricides has previously reported excellent effectiveness of its earlier drug candidates in the HerpeCide™ program against the highly pathogenic, neurotropic strain of HSV-1, namely H129, leading to full survival of lethally infected mice. Since then, the Company has further improved these candidates. The resulting drug candidates have shown excellent efficacy in cell cultures against HSV-1, HSV-2, as well as VZV (aka the chickenpox virus, which is also the cause of shingles).
- Simply Wall St.•8 months ago
Is NanoViricides Inc’s (NYSEMKT:NNVC) CEO Paid Enough Relative To Peers?
Eugene Seymour took the helm as NanoViricides Inc’s (AMEX:NNVC) CEO and grew market cap to US$58.43M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial part ofRead More...
- ACCESSWIRE•8 months ago
Blog Exposure - Shire Gets BLA and Priority Review Status from FDA for Lanadelumab for the Prevention of HAE Attacks
Stock Monitor: NanoViricides Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 26, 2018 / Active-Investors.com has just released a free research report on Shire PLC (NASDAQ: SHPG ). If you want ...
- Associated Press•8 months ago
NanoViricides reports 2Q loss
On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 4 cents. Losses, adjusted to extinguish debt, were 2 cents per share. The company's shares closed at 97 cents. A year ...
- PR Newswire•8 months ago
NanoViricides Files Quarterly Report for Period Ending December 31, 2017
SHELTON, Conn., Feb. 21, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its second quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission on Tuesday, February 20, 2018. The Company reported that it had approximately $12.0 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of December 31, 2017, the end of the reporting period. The Company's research and development (R&D) expenditure of approximately $1.4M in the current quarter was in line with our budgeted estimates.
- Simply Wall St.•8 months ago
How Does NanoViricides Inc (NYSEMKT:NNVC) Affect Your Portfolio Returns?
For NanoViricides Inc’s (AMEX:NNVC) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measures NNVC’sRead More...
- Simply Wall St.•8 months ago
Who Are The Largest Shareholders In NanoViricides Inc (NYSEMKT:NNVC)?
In this article, I’m going to take a look at NanoViricides Inc’s (AMEX:NNVC) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
- PR Newswire•11 months ago
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
SHELTON, Conn. , Dec. 6, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that it has begun initial safety and toxicology evaluation of its optimized nanoviricides® ...
- Simply Wall St.•11 months ago
Is NanoViricides Inc (NNVC) A Financially Sound Company?
While small-cap stocks, such as NanoViricides Inc (AMEX:NNVC) with its market cap of USD $63.34M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
- PR Newswire•11 months ago
NanoViricides Files Quarterly Report for Period Ending September 30, 2017
SHELTON, Conn., Nov. 20, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its first quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission on Tuesday, November 14, 2017. NanoViricides reported that it had approximately $13.7 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of September 30, 2017, the end of the reporting period. The net cash used in operating activities during this quarter was approximately $1.56 M. The Company's research and development (R&D) expenditure have decreased for the quarter but are in line with our budgeted estimates.
- ACCESSWIRE•11 months ago
NanoViricides Signs Extension of Herpes Virus (HSV) Testing Agreement with University of Wisconsin
SHELTON, CT / ACCESSWIRE / November 8, 2017 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") has announced that it has extended and expanded its in vivo testing agreement with researchers ...
